Similar articles for PMID: 33517299

Year	Number of Results
1999	1
2002	3
2003	2
2004	3
2005	5
2006	1
2007	2
2008	4
2009	1
2010	2
2011	2
2012	6
2013	6
2014	7
2015	12
2016	11
2017	11
2018	18
2019	15
2020	16
2021	5

1

Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.

Kabadi SM, Byfield SD, LE L, Olufade T. Kabadi SM, et al. Anticancer Res. 2021 Feb;41(2):927-936. doi: 10.21873/anticanres.14846. Anticancer Res. 2021. PMID: 33517299

2

Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.

Kabadi SM, Near A, Wada K, Burudpakdee C. Kabadi SM, et al. Cancer Med. 2019 Dec;8(17):7174-7185. doi: 10.1002/cam4.2559. Epub 2019 Oct 8. Cancer Med. 2019. PMID: 31595715 Free PMC article.

3

Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.

Kabadi SM, Near A, Wada K, Burudpakdee C. Kabadi SM, et al. Adv Ther. 2020 Jul;37(7):3129-3148. doi: 10.1007/s12325-020-01350-w. Epub 2020 May 12. Adv Ther. 2020. PMID: 32399812

4

Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.

Sabater E, López-Guillermo A, Rueda A, Salar A, Oyagüez I, Collar JM. Sabater E, et al. Appl Health Econ Health Policy. 2016 Aug;14(4):465-477. doi: 10.1007/s40258-016-0243-4. Appl Health Econ Health Policy. 2016. PMID: 27090915

5

What is the optimal initial management of the older MCL patient?

Kluin-Nelemans JC, Doorduijn JK. Kluin-Nelemans JC, et al. Best Pract Res Clin Haematol. 2018 Mar;31(1):99-104. doi: 10.1016/j.beha.2017.07.006. Epub 2017 Jul 19. Best Pract Res Clin Haematol. 2018. PMID: 29452672 Review.

6

R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.

Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS. Widmer F, et al. Ann Hematol. 2018 Feb;97(2):277-287. doi: 10.1007/s00277-017-3180-x. Epub 2017 Nov 16. Ann Hematol. 2018. PMID: 29147847

7

Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.

[No authors listed] [No authors listed] Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):9-11. Clin Adv Hematol Oncol. 2014. PMID: 25768994 No abstract available.

8

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W. Lenz G, et al. J Clin Oncol. 2005 Mar 20;23(9):1984-92. doi: 10.1200/JCO.2005.08.133. Epub 2005 Jan 24. J Clin Oncol. 2005. PMID: 15668467 Clinical Trial.

9

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.

Drach J, Huang H, Samoilova O, Belch A, Farber C, Bosly A, Novak J, Zaucha J, Dascalescu A, Bunworasate U, Masliak Z, Vilchevskaya K, Robak T, Pei L, Rooney B, van de Velde H, Cavalli F. Drach J, et al. Leuk Lymphoma. 2018 Apr;59(4):896-903. doi: 10.1080/10428194.2017.1365855. Epub 2018 Jan 17. Leuk Lymphoma. 2018. PMID: 29338540 Clinical Trial.

10

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.

Burke JM, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Simpson D, Craig M, Kolibaba K, Issa S, Munteanu M, Victor TW, Flinn IW. Burke JM, et al. Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):182-190.e1. doi: 10.1016/j.clml.2016.01.001. Epub 2016 Jan 15. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26875824 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed